

Table S1. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate UC (sensitivity analysis)

A. Induction of clinical and endoscopic remission

Budesonide-MMX			
1.23 (0.69–2.20)	Mesalamine >2.4 g/day		
1.54 (0.87–2.71)	1.25 (1.02–1.53)	Mesalamine 1.6–2.4 g/day	
3.48 (2.01–6.04)	2.84 (2.01–4.00)	2.27 (1.62–3.18)	Placebo

B. Serious adverse events (SAEs)

Budesonide-MMX			
1.19 (0.35–4.01)	Mesalamine >2.4 g/day		
0.94 (0.31–2.81)	0.79 (0.41–1.54)	Mesalamine 1.6–2.4 g/day	
0.80 (0.31–2.09)	0.68 (0.27–1.69)	0.86 (0.39–1.87)	Placebo

C. Treatment discontinuations or withdrawals from the study due to adverse events (WDAEs)

Budesonide-MMX			
2.03 (1.09–3.78)	Mesalamine >2.4 g/day		
1.57 (0.88–2.79)	0.77 (0.52–1.15)	Mesalamine 1.6–2.4 g/day	
0.82 (0.52–1.30)	0.41 (0.25–0.66)	0.53 (0.34–0.82)	Placebo

Footnote: The column-defining treatment is compared with the row-defining treatment. The estimates in the cells are odds ratios (ORs) with 95% confidence intervals. For induction of clinical and endoscopic remission, ORs higher than 1.0 favour the treatment in the left upper square. On the opposite, for safety outcomes (SAEs and WDAEs), ORs lower than 1.0 favour the treatment in the left upper square. Statistically significant results are shown in bold.

Abbreviation: UC, ulcerative colitis.

Table S2. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate UC (sensitivity analysis)

A. Induction of clinical and endoscopic remission

	SUCRA value (%)	Probability Best (%)	Mean Rank
Budesonide-MMX	89.6	75.5	1.3
Mesalamine >2.4 g/day	74.4	24.4	1.8
Mesalamine 1.6–2.4 g/day	36.0	0.1	2.9
Placebo	0.0	0.0	4.0

B. Serious adverse events (SAEs)

	SUCRA value (%)	Probability Best (%)	Mean Rank
Budesonide-MMX	53.3	32.9	2.4
Mesalamine >2.4 g/day	72.3	49.9	1.8
Mesalamine 1.6–2.4 g/day	45.2	10.6	2.6
Placebo	29.2	6.6	3.1

C. Treatment discontinuations or withdrawals from the study due to adverse events (WDAEs)

	SUCRA value (%)	Probability Best (%)	Mean Rank
Budesonide-MMX	28.8	0.8	3.1
Mesalamine >2.4 g/day	96.3	89.5	1.1
Mesalamine 1.6–2.4 g/day	68.0	9.7	2.0
Placebo	7.0	0.0	3.8

Footnote: Herein we present: (i) the SUCRA values providing the hierarchy of the competing treatments, (ii) the estimated probabilities of each treatment being the best, and (iii) the mean rank of each treatment using 10,000 draws.

Abbreviation: UC, ulcerative colitis.

Table S3. Networks' assessment for homogeneity and consistency (**sensitivity analysis**)

Outcome	Heterogeneity (restricted likelihood ratio test)	Inconsistency (global Wald test)
Induction of clinical and endoscopic remission	<i>p</i> -value = 0.25	<i>p</i> -value = 0.93
Serious adverse events (SAEs)	<i>p</i> -value = 0.99	<i>p</i> -value = 0.91
Treatment discontinuations or withdrawals from the study due to adverse events (WDAEs)	<i>p</i> -value = 0.99	<i>p</i> -value = 0.48